14 Sep One Size Fits All Strategy No Longer Works For Treatment of Ovarian Cancer
MedicalResearch.com Interview with:
Dr. Larissa Meyer
Larissa A. Meyer, MD MPH F.A.C.O.G.
Assistant Professor
Dept of Gynecologic Oncology and Reproductive Medicine
Houston, TX 77030-1362
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Despite the completion of two randomized controlled trials, controversy regarding the optimal approach for the treatment of advanced ovarian cancer remains. Our observational study highlights the importance of thoughtful selection of individuals for primary cytoreductive surgery for advanced ovarian cancer. Our results suggest that primary cytoreductive surgery may improve survival for patients with stage IIIC ovarian cancer who are likely to achieve an optimal cytoreduction, while neoadjuvant chemotherapy may be the preferred option for many women with stage IV ovarian cancer.
MedicalResearch.com: What should readers take away from your report?
Response: The bottom line is a one-size-fits all strategy no longer works for the treatment of advanced ovarian cancer.
MedicalResearch.com: Is there anything else you would like to add?
Response: The findings in our study are aligned with the recently issued ASCO/SGO guideline for neoadjuvant chemotherapy (NACT). In fact, several of the authors of the recent guideline were authors in this study. For example, in Recommendation 3.2. of the bottom line box of the guidelines, we stated that “for women with a high likelihood of achieving cytoreduction to < 1 cm (ideally to no visible disease disease) with acceptable morbidity, PCS is recommended over NACT.” Our findings support this recommendation.
The subsequent recommendation in the guidelines, Recommendation 3.3. states that “for women who are fit for PCS but are deemed unlikely to have cytoreduction to
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
Citation:
Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer
Larissa A. Meyer, Angel M. Cronin, Charlotte C. Sun, Kristin Bixel, Michael A. Bookman, Mihaela C. Cristea, Jennifer J. Griggs, Charles F. Levenback, Robert A. Burger, Gina Mantia-Smaldone, Ursula A. Matulonis, Joyce C. Niland, David M. O’Malley, and Alexi A. Wright
JCO JCO681239; published online on September 6, 2016;
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.
More Medical Research Interviews on MedicalResearch.com
[wysija_form id=”5″]
Last Updated on September 14, 2016 by Marie Benz MD FAAD